Previous 10 | Next 10 |
Heron Therapeutics (HRTX) has added ~16.6% in the premarket after announcing that its postoperative painkiller ZYNRELEF (bupivacaine and meloxicam) was approved by the FDA.Given the side effects, the regulator has licensed ZYNRELEF with a Boxed Warning and it is indicated for &...
Palisade Bio (PALI) +36% on FDA's fast track designation for LB1148.Fuel Tech (FTEK) +21% on Q1 results.Lianluo Smart (LLIT) +20%.Celyad Oncology SA (CYAD) +20%.Vertex Energy (VTNR) +18% on Q1 results.InnSuites Hospitality Trust (IHT) +15%.Heron Therapeutics (HRTX) +15% on...
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours - ZYNRELEF is the first and only FDA-approved extended-release dual-acting local anesthetic, clinically proven to manage pain and to eliminate...
Shares of Heron Therapeutics (NASDAQ: HRTX) were jumping 7.3% as of 3:08 p.m. EDT on Monday after rising as much as 13% earlier in the day. The gain came after the drugmaker provided its first-quarter update Monday morning. Heron announced Q1 revenue of $20 million, down 21% yea...
Heron Therapeutics (HRTX) is trading sharply higher despite its lower-than-expected financial results for Q1 2021. The management remarks over an impending FDA decision for the company’s investigational non-opioid analgesic appear to have caused the rally.The New Drug Applica...
Heron Therapeutics (HRTX): GAAP EPS of -$0.58 misses by $0.03.Revenue of $20M (-21.3% Y/Y) misses by $5.73M.Cash, cash equivalents and short-term investments of $166.5MHeron expects that its current cash, cash equivalents and short-term investments will be sufficient to fund its operatio...
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corporate Updates - Labelling Discussions with the FDA are Underway for HTX-011; Prescription Drug User Fee Act (PDUFA) Goal Date is May 12, 2021 - PR Newswire ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The corporate earnings season slows down just a bit, but the conference and event schedule heats up with the Sohn Invest...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...
Biotech investors live and die by the binary news events generated by the drugmakers they invest in. Heron Therapeutics (NASDAQ: HRTX) , for instance, is awaiting a decision from the Food and Drug Administration about its candidate HTX-011 for use in post-operative pain. Likewise, ...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...